Indication
Acute GVHD
6 clinical trials
7 products
Product
OSSM-001Clinical trial
A Phase I Safety Study of Single Dose Allogeneic Bone Marrow Derived MSCs for Steroid Refractory Acute Graft vs. Host DiseaseStatus: Withdrawn, Estimated PCD: 2024-06-10
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study of Itolizumab in Combination With Corticosteroids for the Initial Treatment of Acute Graft Versus Host DiseaseStatus: Recruiting, Estimated PCD: 2024-07-01
Product
ItolizumabProduct
EQ001Clinical trial
Development of a Population Pharmacokinetic Model to Optimize Tacrolimus Dosing in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplant.Status: Completed, Estimated PCD: 2023-10-15
Product
TacrolimusClinical trial
Phase II Clinical Trial of 2 Step ATG Combined With Tacrolimus and Mini Methotrexate for Prevention of Acute GVHD Post Myeloablative Allogeneic Stem Cell TransplantStatus: Not yet recruiting, Estimated PCD: 2025-10-29
Clinical trial
Wharton's Jelly Mesenchymal Stromal Cell (WG-MSC) Injections as GVHD Prophylaxis in Hematopoietic Allogeneic Stem Cell Transplantation With an Haplo-identical Donor : a Dose Escalation StudyStatus: Not yet recruiting, Estimated PCD: 2025-09-01
Product
WJ-MSC infusionClinical trial
Phase I, First in Human, Open Label Study to Evaluate Safety and Tolerability of TRX103 Cells in Subjects With Hematological Malignancies Undergoing HLA-mismatched Related or Unrelated Hematopoietic Stem Cell Transplantation (HSCT)Status: Recruiting, Estimated PCD: 2026-04-15
Product
TRX103